Literature DB >> 10543759

The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents.

D Sanglard1, F Ischer, D Calabrese, P A Majcherczyk, J Bille.   

Abstract

The resistance mechanisms to azole antifungal agents were investigated in this study with two pairs of Candida glabrata clinical isolates recovered from two separate AIDS patients. The two pairs each contained a fluconazole-susceptible isolate and a fluconazole-resistant isolate, the latter with cross-resistance to itraconazole and ketoconazole. Since the accumulation of fluconazole and of another unrelated substance, rhodamine 6G, was reduced in the azole-resistant isolates, enhanced drug efflux was considered as a possible resistance mechanism. The expression of multidrug efflux transporter genes was therefore examined in the azole-susceptible and azole-resistant yeast isolates. For this purpose, C. glabrata genes conferring resistance to azole antifungals were cloned in a Saccharomyces cerevisiae strain in which the ATP binding cassette (ABC) transporter gene PDR5 was deleted. Three different genes were recovered, and among them, only C. glabrata CDR1 (CgCDR1), a gene similar to the Candida albicans ABC transporter CDR genes, was upregulated by a factor of 5 to 8 in the azole-resistant isolates. A correlation between upregulation of this gene and azole resistance was thus established. The deletion of CgCDR1 in an azole-resistant C. glabrata clinical isolate rendered the resulting mutant (DSY1041) susceptible to azole derivatives as the azole-susceptible clinical parent, thus providing genetic evidence that a specific mechanism was involved in the azole resistance of a clinical isolate. When CgCDR1 obtained from an azole-susceptible isolate was reintroduced with the help of a centromeric vector in DSY1041, azole resistance was restored and thus suggested that a trans-acting mutation(s) could be made responsible for the increased expression of this ABC transporter gene in the azole-resistant strain. This study demonstrates for the first time the determinant role of an ABC transporter gene in the acquisition of resistance to azole antifungals by C. glabrata clinical isolates.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543759      PMCID: PMC89555     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  56 in total

1.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

2.  Techniques for investigation of an apparent outbreak of infections with Candida glabrata.

Authors:  S Arif; T Barkham; E G Power; S A Howell
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

3.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

4.  ATPase and multidrug transport activities of the overexpressed yeast ABC protein Yor1p.

Authors:  A Decottignies; A M Grant; J W Nichols; H de Wet; D B McIntosh; A Goffeau
Journal:  J Biol Chem       Date:  1998-05-15       Impact factor: 5.157

5.  The pMTL nic- cloning vectors. I. Improved pUC polylinker regions to facilitate the use of sonicated DNA for nucleotide sequencing.

Authors:  S P Chambers; S E Prior; D A Barstow; N P Minton
Journal:  Gene       Date:  1988-08-15       Impact factor: 3.688

6.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

Review 7.  Antifungal drug resistance in pathogenic fungi.

Authors:  H Vanden Bossche; F Dromer; I Improvisi; M Lozano-Chiu; J H Rex; D Sanglard
Journal:  Med Mycol       Date:  1998       Impact factor: 4.076

8.  Molecular cloning and expression of the Saccharomyces cerevisiae STS1 gene product. A yeast ABC transporter conferring mycotoxin resistance.

Authors:  P H Bissinger; K Kuchler
Journal:  J Biol Chem       Date:  1994-02-11       Impact factor: 5.157

9.  Fluconazole resistance in Candida glabrata.

Authors:  C A Hitchcock; G W Pye; P F Troke; E M Johnson; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

10.  Post-mortem findings in patients with repeatedly mycological demonstration of Candida glabrata.

Authors:  I Vennewald; C Seebacher; E Roitzsch
Journal:  Mycoses       Date:  1998 Mar-Apr       Impact factor: 4.377

View more
  144 in total

1.  Management of Infections Caused by Candida glabrata.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

Review 2.  Mechanisms of fungal resistance: an overview.

Authors:  Maher M Balkis; Steven D Leidich; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

Review 4.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

5.  The Rho1 GTPase-activating protein CgBem2 is required for survival of azole stress in Candida glabrata.

Authors:  Sapan Borah; Raju Shivarathri; Rupinder Kaur
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

6.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

7.  Enhanced Efflux Pump Activity in Old Candida glabrata Cells.

Authors:  Somanon Bhattacharya; Bettina C Fries
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

8.  Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrata.

Authors:  Sarah G Whaley; Qing Zhang; Kelly E Caudle; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

9.  In vitro and in vivo effects of 14alpha-demethylase (ERG11) depletion in Candida glabrata.

Authors:  H Nakayama; N Nakayama; M Arisawa; Y Aoki
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.